From zero to top 5, YHLO only took 4 years to rank high in Chinese CLIA in vitro diagnostic tests field.

Shenzhen YHLO Biotech grows rapidly into one of the top 5 chemiluminescence immunoassay (CLIA) brand of in vitro diagnostic tests industry in China from 2016 (the first CLIA analyzer was born) to date. A reporter from IVD China reported YHLO’s regular return visit lead by YHLO chairman, Michael Hu, to 8 hospitals in Beijing, China, September.

As a leading company of immunoassay solutions, YHLO’s core products have gained recognition from professionals in the field. Top Chinese hospitals including Fuwai Hospital, Peking Union Medical College Hospital (PUMCH), Beijing Hospital and more have been cooperating with YHLO for years. What’s more, over 50% triple A hospitals are using YHLO products now.

In 2019, YHLO stood out from many manufacturers for the qualification of supplying antiphospholipid antibody (APS) tests for Peking Union Medical College Hospital. The qualification didn’t come easy, as the test results of APS are very unstable and difficult, which greatly tested the supplier's product quality. After a rigorous clinical comparison and verification of large samples, YHLO finally outshined others by virtue of its excellent testing quality, and became a reliable partner of PUMCH until today.

“Autoimmune diagnosis is one of the fastest developing tests in the past 10 years”, said Dr.Hu Chaojun, head of the Laboratory of Rheumatology and Immunology at PUMCH. YHLO is one of the very few manufacturers in the industry that can provide unique tests for autoimmunity, developed more than 40 CLIA products for autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, Sjogren’s syndrome, autoimmune vasculitis, autoimmune liver disease, etc.. YHLO occupies a very important position in PUMCH Rheumatology and Immunology Laboratory.

Fuwai Hospital is specializing in cardiovascular diseases, well known internationally for treatment of all kinds of complex, difficult, and severe cardiovascular diseases, and has become the world's biggest cardiovascular center. Dr. Zhou, Director of Laboratory Diagnosis Center, Fuwai Hospital, said, "The antiphospholipid antibody project in cooperation with YHLO is a new field that we have developed together with more than a dozen hospitals. Through this we hope that we can better help doctors to develop some ground-breaking indicators in scientific research and clinical research." In fact, cardiovascular and autoimmune have a deep crossover - autoimmune related tests have many applications in cardiovascular diseases. YHLO has achieved fruitful academic achievements in areas such as SARS-Cov-2, self-immunization, reproduction, diabetes, and low-risk infections.

Michael Hu indicated that, in the next 3-5 years, YHLO will focus on three goals: to build a Chinese benchmark brand in the field of autoimmune disease diagnosis, to deepen the field of reproduction and create YHLO's influence, to continue to develop and innovate the chemiluminescence technology platform and other cutting-edge technologies.

About YHLO

Shenzhen YHLO Biotech Co., Ltd. (YHLO) is a leading company of immunoassay solutions in China. Founded in 2008, listed on the Shanghai Stock Exchange in 2021, YHLO is headquartered in Shenzhen, China, specialized in developing, manufacturing and distributing in-vitro diagnostic instruments and reagents by a team of experienced scientists and engineers.

YHLO launched its first CLIA instrument in 2016, the iFlash 3000, which is China’s first high throughput CLIA analyzer. Since that, YHLO launched iFlash 1800 (bench-top CLIA) in 2017, iModules Modular System in 2019, iFlash 1200 in 2021, and developed over 120 parameters for CLIA platform.

YHLO has strategic cooperation with famous universities, research institutes and high-tech enterprises from the USA, Germany, Italy, etc., dedicated to meeting global clinical demands and developing instruments and reagents with our own intellectual properties. By March 2021, YHLO had applied for 314 patents, and over 92 patents were granted.

Source: https://mp.weixin.qq.com/s/ltbfnX3LR2kUAWvB1Jk7wQ